Skip to main content
Lakshmi Nayak, MD, Oncology, Boston, MA

LakshmiNayakMD

Oncology Boston, MA

Instructor, Neurology-Brigham & Women's Hospital, Harvard Medical School

Dr. Nayak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Nayak's full profile

Already have an account?

  • Office

    450 Brookline Ave
    Boston, MA 02215
    Phone+1 617-632-2166
    Fax+1 617-632-4773

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 2006 - 2009
  • New York Downtown Hospital
    New York Downtown HospitalResidency, Internal Medicine, 2004 - 2006
  • Grant Medical College
    Grant Medical CollegeClass of 2002

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • ME State Medical License
    ME State Medical License Current
  • MA State Medical License
    MA State Medical License 2011 - 2026
  • NY State Medical License
    NY State Medical License 2011 - 2013
  • PA State Medical License
    PA State Medical License 2009 - 2010
  • American Board of Psychiatry and Neurology Neurology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Turning the Corner in Relapsed/Refractory CNS Lymphoma: Applying Precision and Immune-Based... 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
  • Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with r... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

  • Kazia Enters Clinical Collaboration with Dana-Farber Cancer Institute for Primary CNS Lymphoma
    Kazia Enters Clinical Collaboration with Dana-Farber Cancer Institute for Primary CNS LymphomaSeptember 22nd, 2020
  • The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in Funding
    The Leukemia & Lymphoma Society (LLS) Fuels the Next Generation of Cancer Research Committing More Than $188 Million in FundingNovember 8th, 2018
  • Immunotherapy Agent Yields Full and Partial Remissions in Aggressive Non-Hodgkin Lymphomas
    Immunotherapy Agent Yields Full and Partial Remissions in Aggressive Non-Hodgkin LymphomasDecember 5th, 2016
  • Join now to see all

Professional Memberships